Buys royalty streams on approved and pipeline biopharma drugs, collecting a cut of sales without doing R&D itself.
Buys royalty streams on approved and pipeline biopharma drugs, collecting a cut of sales without doing R&D itself.
Pays upfront to buy a share of a drug's future sales, then collects a percentage of those sales for years, so income follows how well other companies' drugs sell. Its largest streams come from a few big drugs, notably the cystic fibrosis medicines sold by Vertex, a royalty it bought from the Cystic Fibrosis Foundation in 2014.
Moat: narrow (scale, distribution). Large capital base and industry relationships let it win bigger royalty deals than smaller rivals.
Headquarters: London, United Kingdom · Founded: 1996 · Employees: 100
Size Royalty Pharma (RPRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $39.4B, the 300th largest of 3,085 United States companies the cockpit tracks. Shares closed at $68.67 on 18 Nov 2026.
Performance Over six months the shares gained 29.4%, against +13.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue grew 11.3% over the last twelve months (peer median +16.4%); the operating margin is 65.5% (peer median 17.8%).
Valuation It trades at 11.5× forward earnings against a peer median of 19.0× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.7 points above its cost of capital (6.6% WACC).
Credit Royalty Pharma has 11 bonds outstanding ($7.80B), rated BBB by the agencies and trading like A- at a weighted spread of 96 bp.
Short interest Short interest is 2.9% of the free float (30 Oct 2026).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.62B | $2.38B | $2.26B | $2.35B | $2.24B |
| Revenue growth | — | +5% | -4% | +5% | — |
| Gross profit | $2.61B | $2.37B | n/a | n/a | $2.23B |
| EBITDA | $1.72B | $1.56B | $1.29B | $1.49B | $929M |
| Net income | $671M | $771M | $859M | $1.13B | $42.8M |
| Free cash flow | $2.99B | $2.59B | $2.79B | $3.03B | $2.14B |
| Capital expenditure | $1.72B | $1.70B | $2.52B | $2.12B | $1.76B |
| Total debt | $8.59B | $8.97B | $7.61B | $6.14B | $7.12B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Royalty Pharma RPRX | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% |
| Ligand Pharmaceuticals LGND | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% |
| Innoviva INVA | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RPRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.3% | +5.0% | 6th highest of 21 |
| 6-month return | +29.4% | +13.3% | 5th highest of 21 |
| Distance from 52-week high | -2.4% | -9.1% | 2nd highest of 21 |
| Revenue growth (TTM) | +11.3% | +16.4% | 8th lowest of 21 |
| Operating margin | 65.5% | 17.8% | highest of 21 |
| Forward P/E | 11.5× | 19.0× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 10.8% | 9.1% | 8th most demanding of 18 |
| Growth delivered (Del g) | +2.3% | +10.8% | 5th lowest of 18 |
| Hurdle (Req g minus delivered) | +8.5 pp | +2.8 pp | 5th most demanding of 18 |
| ROIC minus cost of capital | +0.7 pp | +4.8 pp | 8th lowest of 21 |
| EV / EBITDA | 29.3× | 18.9× | 5th most expensive of 17 |
| Net debt / EBITDA | 4.7× | 0.8× | most indebted of 17 |
| Bond spread | 96 bp | 100 bp | 4th tightest of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Jiangsu Hengrui Pharmaceuticals 1276.HK | Hong Kong | $44.9B | -24% | +11% | 27% | 28.1× | 9.1% | +2.0% |
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |
| Wuxi Apptec 2359.HK | Hong Kong | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% | +20.4% |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 15.1× | 14.2% | +14.0% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% | +3.7% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 38.4× | 28.9% | +26.1% |
Royalty Pharma has 11 bonds outstanding with $7.80B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.86%, a spread of 96 bp over government bonds.